Roche set to extend Hemlibra labelThe US FDA has accepted a supplemental BLA to Roche’s existing market approval of the new hemophilia A treatment Hemlibra (emicizumab), which could significantly extend the patient group covered by the … more ➔
EMA recommends nine drugs for approvalThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines, at its May 2018 meeting. more ➔
Denali bags F-Star GammaBrain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain … more ➔
Roche mets endpoints in first-line NSCLC studyRoche announced that atezolimumab plus chemotherapy met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment of stage IV nonsquamous non small … more ➔
New way to safer CAR-T cell therapiesInterleukin 1 (IL-1) blockers may prevent serious adverse events triggered by CAR-T cell therapies, according to two independent studies. more ➔
Janssen ends combo with daratumumabFollowing reports of an increase in mortality in a study that combined Genmab’s anti-CD38 daratumumab with a PD-L1 blocker, Genmab’s partner Janssen has stopped a study combining daratumumab with its PD1 … more ➔
Targovax drug boosts 2-year OS in pancreatic cancerTargovax ASA’s cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax’ shares were up 16% on Thursday … more ➔
Researchers target metastasesItalian oncologists have found a more effective tumour angiogenesis blocker which curbs metastasis and tumour growth. more ➔
Vifor Pharma in €70m pruritus drug dealVifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated … more ➔
